Aura Biosciences, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$5.90
−$0.09 (−1.42%) 4:00 PM ET
Prev closePrevC$5.98
OpenOpen$5.98
Day highHigh$6.09
Day lowLow$5.72
VolumeVol157,651
Avg volAvgVol197,321
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$374.03M
P/E ratio
-3.04
EPS
-1.94
Sector
Healthcare
AI report sections
MIXED
AURA
Aura Biosciences, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−23% (Below avg)
Vol/Avg: 0.77×
RSI
59.48(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.02 Signal: 0.01
Short-Term
+0.06 (Strong)
MACD: 0.05 Signal: -0.01
Long-Term
+0.05 (Strong)
MACD: -0.05 Signal: -0.10
Intraday trend score
49.00
LOW49.00HIGH63.00
Latest news
AURA•12 articles•Positive: 5Neutral: 2Negative: 0
NeutralGlobeNewswire Inc.• Elisabet De Los Pinos, Phd
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences, a clinical-stage biotechnology company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, discussing their precision therapies for solid tumors.
The article is a neutral announcement about a company presentation, highlighting ongoing clinical development without significant positive or negative indicators
NeutralThe Motley Fool• Jesterai
Aura Biosciences Posts Q2 Cash Surge
Aura Biosciences reported Q2 2025 financial results, highlighting continued clinical development of bel-sar for ocular and bladder cancers, raising $75 million in equity, and maintaining a cash runway into early 2027.
The company showed mixed performance with continued clinical progress, increased R&D spending, a successful equity raise, but persistent net losses typical of late-stage biotech firms
PositiveGlobeNewswire Inc.• Aura Biosciences
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported Q2 2025 financial results, highlighting ongoing clinical trials for bel-sar in early choroidal melanoma and non-muscle invasive bladder cancer. The company raised $75 million in equity financing and expects cash to fund operations into the first half of 2027.
Strong financial position with $177.3 million cash, ongoing clinical trials, successful equity financing, and expansion of clinical programs across multiple oncology indications
PositiveBenzinga• Globe Newswire
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Aura Biosciences announced the pricing of a public offering of common stock and warrants, raising $75 million. The company plans to use the proceeds to advance its clinical programs in various cancer indications.
The company is raising $75 million through a public offering, which will be used to advance its clinical programs in various cancer indications, indicating a positive outlook for the company's growth and development.
PositiveGlobeNewswire Inc.• N/A
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Aura Biosciences, a clinical-stage biotechnology company, announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to its Board of Directors. Bitetti's extensive operational and commercial experience will be valuable as Aura advances its clinical pipeline in ocular and urologic oncology.
AURATAKAura BiosciencesTakedaoncologyboard of directors
Sentiment note
The article highlights Aura Biosciences' appointment of a seasoned industry leader to its board, which is seen as a positive development for the company as it advances its clinical pipeline.
PositiveGlobeNewswire Inc.• N/A
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura Biosciences announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of non-muscle invasive bladder cancer will be presented at the European Association of Urology Congress. The company will also host a virtual investor event to discuss the data and provide a program update.
AURAAura Biosciencesbladder cancerbel-sarPhase 1 trialEuropean Association of Urology Congress
Sentiment note
The article highlights Aura Biosciences' progress in its bladder cancer program, including the presentation of additional Phase 1 data and plans for a virtual investor event to discuss the data and provide a program update. This suggests the company is making advancements in its clinical development efforts.
3 Small-Cap Stocks Ready to Deliver Significant Growth
The article discusses three small-cap stocks that are poised for significant growth due to the Federal Reserve's recent interest rate cuts, which are expected to benefit small-cap companies that rely heavily on debt to fuel their growth.
The clinical-stage biotech company has seen positive results from its Phase 2 study of a treatment for certain types of ocular cancers, driving analyst optimism and a consensus price target significantly above the current stock price.
UnknownZacks Investment Research• Zacks Equity Research
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
By selling these assets, UnitedHealth (UNH) and Amedisys aim to avoid potential monopoly issues and ensure a smoother merger process.
UNHAMEDAURAELV
UnknownZacks Investment Research• Zacks Equity Research
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
AURA
UnknownZacks Investment Research• Zacks Equity Research
Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak
Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.
BKDHQYSERAAURA
UnknownZacks Investment Research• Zacks Equity Research
Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 162.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AURA
UnknownGlobeNewswire Inc.• Aura Biosciences, Inc.
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET.
AURACalendar of EventsConference Calls/ Webcasts
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
